Glenmark Pharmaceuticals S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) has discovered and initiated IND enable studies of a novel clinical development candidate, GBR 830, an anti-OX40 monoclonal antibody.
GBR 830 has been discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 830, an anti-OX40 monoclonal antibody is a potential Global First-in-class molecule
OX40 is a well known target and the development of OX40 antagonists has been very challenging. The company has achieved a significant milestone with the successful generation of an antagonistic OX40 monoclonal antibody coupled with generation of data validating the role of OX40 in autoimmune diseases.
GBR 830 shows great promise to emerge as a valuable therapeutic option to treat patients suffering from immune pathologies such as autoimmune diseases like Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1826.10 |
Dr. Reddys Lab | 1371.60 |
Cipla | 1488.15 |
Lupin | 2251.80 |
Zydus Lifesciences | 1009.40 |
View more.. |